A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer

被引：0
|
作者：
Loesch, D. M.
Greco, F.
O'Shaughnessy, J.
Hainsworth, J. D.
Vukelja, S. J.
Sandbach, J.
Boehm, K. A.
Ilegbodu, D.
Asmar, L.
Robert, N. J.
机构：
[1] US Oncol Res Inc, Houston, TX USA
[2] Cent Indiana, Indianapolis, IN USA
[3] Minnie Pearl Clin Res, Sarah Cannon Canc Ctr, Nashville, TN USA
[4] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[5] Tyler Canc Ctr, Tyler, TX USA
[6] Texas Oncol Canc Ctr, Austin, TX USA
[7] Fairfax Northern Virginia Hematol Oncol, Fairfax, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
517
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized, multicenter phase III trial comparing regimens of doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer
    Loesch, D
    Greco, FA
    O'Shaughnessy, J
    Asmar, L
    Senzer, NN
    Burris, HA
    Hainsworth, JD
    Vukelja, S
    Sandbach, J
    Holmes, F
    Sedlacek, S
    Lindquist, D
    Pippen, J
    Olivares, J
    Boehm, KA
    Zhan, F
    Robert, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S17
  • [2] Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer
    Loesch, David
    Greco, F. Anthony
    Senzer, Neil N.
    Burris, Howard A.
    Hainsworth, John D.
    Jones, Stephen
    Vukelja, Svetislava J.
    Sandbach, John
    Holmes, Frankie
    Sedlacek, Scot
    Pippen, John
    Lindquist, Deborah
    McIntyre, Kristi
    Blum, Joanne L.
    Modiano, Manuel R.
    Boehm, Kristi A.
    Zhan, Feng
    Asmar, Lina
    Robert, Nicholas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 2958 - 2965
  • [3] Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer
    Cho, E.
    Wu, Q.
    Rubinstein, L.
    Linden, H.
    Gralow, J.
    Specht, J.
    Gadi, V.
    Ellis, G.
    [J]. CANCER RESEARCH, 2017, 77
  • [4] SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer.
    Ellis, G. K.
    Green, S. J.
    Russell, C. A.
    Royce, M. E.
    Perez, E. A.
    Livingston, R. B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 12S - 12S
  • [5] A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel plus sorafenib in women with node positive or high-risk breast cancer.
    Spigel, D. R.
    Molthrop, D.
    Peacock, N.
    Kommor, M.
    Markus, T.
    Vazquez, E.
    Greco, F. A.
    Burris, H. A.
    Hainsworth, J. D.
    Yardley, D. A.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 190S - 190S
  • [6] SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer
    Ellis, G. K.
    Barlow, W. E.
    Russell, C. A.
    Royce, M. E.
    Perez, E. A.
    Livingston, R. B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 933S - 933S
  • [7] A phase II study of doxorubicin plus paclitaxel followed by weekly paclitaxel as neoadjuvant chemotherapy for breast cancer (SBCCSG-07)
    Inoue, K.
    Takei, H.
    Kurozumi, M.
    Futsuhara, K.
    Kai, T.
    Kuroda, T.
    Ueda, S.
    Miyake, H.
    Hakamada, Y.
    Suemasu, K.
    Tabei, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
    Snider, Jessica N.
    Young, Robyn R.
    Schwartzberg, Lee Steven
    Allen, Jeffrey Warren
    Javed, Yasir Ahmed
    Jahanzeb, Mohammad
    Sachdev, Jasgit C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Doxorubicin (Adriamycin, A) plus paclitaxel (T) followed by weekly paclitaxel (wT) as primary chemotherapy for women with locally advanced breast cancer (LABC).
    Zambetti, M
    Mariani, G
    Citterio, G
    Valagussa, P
    Greco, M
    Tomasic, G
    Lozza, L
    Piotti, P
    Gianni, L
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S110 - S110
  • [10] Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
    Diéras, V
    Fumoleau, P
    Romieu, G
    Tubiana-Hulin, M
    Namer, M
    Mauriac, L
    Guastalla, JP
    Pujade-Lauraine, E
    Kerbrat, P
    Maillart, P
    Pénault-Llorca, F
    Buyse, M
    Pouillart, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) : 4958 - 4965
12345